A Phase 1, Open-Label, Randomized, 3-Way Crossover Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Dec 2019
Price : $35 *
At a glance
- Drugs ABI-H2158 (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors Assembly Biosciences
- 26 Nov 2019 Status changed from recruiting to completed.
- 06 Sep 2019 Status changed from planning to recruiting.
- 07 May 2018 According to an Assembly Biosciences media release, this trial is expected to begin in the fourth quarter of 2018.